Texas product liability attorney, Brian Eberstein, reports Pfizer stops CB-1 antagonist class obesity drug production. Pfizer states FDA will require new human trial studies and Pfizer will not pay.
The informed Dallas product liability advocate, Eberstein, asserts prescription drug companies are feeling pressure by U.S. Food and Drug Administration’s (FDA) minimal requirements in some of their recent prescription medication development. Pfizer recently halted work on a CB-1 antagonist class obesity drug. The international drug company has been receiving scrutiny by industry experts for the psychiatric side effects caused by the medication reported during clinical trials. According to Pfizer officials, the new drug had little chance of market approval by the FDA because of the psychiatric side effects. The company further states it was unwilling to pay for new human trial studies, the FDA will most likely require, to prove the drugs safety and efficacy in human use.
Educated Dallas County drug product defect attorney, Eberstein, with the law firm of Eberstein and Witherite discloses the recent stopping of several obesity drug production by large drug manufacturers:
-Sanofi-Aventis suspended European sales of its CB-1 antagonist, Acomplia in October
-FDA refused U.S. Approval of Acomplia in 2007
-Merck and Co. recently ceased production of similar drug called Taranabant this
Knowledgeable Texas product liability lawyer, Brian A. Eberstein, has successfully litigated claims for his injured clients due to defective drug products. The skilled victims advocate urges consumers, injured by prescription and over-the-counter medications to contact a product liability attorney for a free consultation. If you or someone you know has been injured by an unsafe medication approved by the FDA you may be entitled to several types of compensation for your injuries and losses.
Media Contact: Brian A. Eberstein
Eberstein & Witherite
3100 Monticello, Suite 500
Dallas, Texas 75205
Toll Free: (888) 407-6669